What is Summit Therapeutics's operating income?

Summit Therapeutics (SMMT) reported operating income of -$65.61M in Q4 2024.

How has Summit Therapeutics's operating income changed year-over-year?

Summit Therapeutics's operating income decreased by 81.2% year-over-year, from -$36.21M to -$65.61M.

What is the long-term trend for Summit Therapeutics's operating income?

Over 3 years (2021 to 2024), Summit Therapeutics's operating income has grown at a 37.9% compound annual growth rate (CAGR), from -$86.19M to -$226M.

Summit Therapeutics SMMT Operating Income

Discontinued — last reported Q4 '24

Operating Income at other companies

ExelixisEXEL

$251.34M+34.5%

IncyteINCY

$301.12M+46.8%

AbbVieABBV

$3.99B+6.9%

Jazz PharmaceuticalsJAZZ

$336.6M+702%

Gilead SciencesGILD

$2.59B+15.6%

Johnson & JohnsonJNJ

——

Other financials

Income statement

See full

Revenue-—

Net income-$189.4M-201%

EPS (diluted)-$0.24-167%

Balance sheet

See full

Cash & equivalents$8.2M+7.2%

Total debt$20.0M+211%

Total equity$545.9M+58.5%

Total assets$647.9M+68.8%

Cash flow

See full

Operating cash flow-$122.3M-99.9%

CapEx$245.0K-41.9%

Free cash flow-$122.5M-99.0%

Valuation

See full

Market cap$10.67B+3.3%

Enterprise value$10.68B+3.4%

Profitability

See full

Operating margin-268,266.8%-272,316pp

Net margin-271,685%-275,966pp

FCF margin-5,931.6%+4,730pp

Returns & leverage

See full

Return on equity-271%-1,725pp

Debt / equity0×0.0×

Current ratio7.4×-3.2×

Where this comes from

Reported directly by Summit Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:OperatingIncomeLoss.

The official record: Summit Therapeutics’s 10-K, filed February 24, 2025, on SEC EDGAR. View the filing →

Ask your AI about Summit Therapeutics's operating income.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Summit Therapeutics's operating income?: Summit Therapeutics (SMMT) reported operating income of -$65.61M in Q4 2024.
How has Summit Therapeutics's operating income changed year-over-year?: Summit Therapeutics's operating income decreased by 81.2% year-over-year, from -$36.21M to -$65.61M.
What is the long-term trend for Summit Therapeutics's operating income?: Over 3 years (2021 to 2024), Summit Therapeutics's operating income has grown at a 37.9% compound annual growth rate (CAGR), from -$86.19M to -$226M.